‘NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma ‘ of page ‘NRG-BN002’
Principal Investigator Mark R. Gilbert, MD Primary Objective Determine the maximum safe dose of single-agent treatment with ipilimumab, nivolumab and the combination when given with temozolomide during maintenance treatment for newly diagnosed glioblastoma. Patient Population Histopathologically proven diagnosis of glioblastoma or gliosarcoma prior to registration by pathology report. The tumor must be unifocal, confined to […]
Read More